Janssen combines Darzalex with COVID-19 drug in new multiple myeloma submissionJanssen has submitted a new combination regimen for its blockbuster multiple myeloma drug Darzalex for approval with the Share XJanssen combines Darzalex with COVID-19 drug in new multiple myeloma submissionhttps://pharmaphorum.com/news/janssen-combines-darzalex-with-covid-drug-in-new-multiple-myeloma-submission/
Scotland backs two myeloma drugs turned down by NICE in EnglandA north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines Consortium (SMC) Share XScotland backs two myeloma drugs turned down by NICE in Englandhttps://pharmaphorum.com/news/scotland-backs-two-myeloma-drugs-tuned-down-by-nice-in-england/
GSK moves further ahead in BCMA with EU okay for BlenrepGlaxoSmithKline has approval on both sides of the Atlantic for its multiple myeloma drug Blenrep, after getting the Share XGSK moves further ahead in BCMA with EU okay for Blenrephttps://pharmaphorum.com/news/gsk-moves-further-ahead-in-bcma-with-eu-okay-for-blenrep/
FDA approves GSK’s Blenrep for advanced multiple myelomaThe FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in Share XFDA approves GSK’s Blenrep for advanced multiple myelomahttps://pharmaphorum.com/news/fda-approves-gsks-blenrep/
BMS ‘bet’ with Celgene shareholders in balance after CAR-T refileBristol-Myers Squibb and bluebird bio have refiled their CAR-T therapy for multiple myeloma, leaving the outcome of a Share XBMS ‘bet’ with Celgene shareholders in balance after CAR-T refilehttps://pharmaphorum.com/news/bms-2/
CHMP gives nod to GSK’s BCMA drug Blenrep for myelomaGlaxoSmithKline is closing in on EU approval for its first-in-class BCMA-targeting drug Blenrep, after getting a green light Share XCHMP gives nod to GSK’s BCMA drug Blenrep for myelomahttps://pharmaphorum.com/news/chmp-gives-nod-to-gsks-bcma-drug-blenrep-for-myeloma/
FDA experts okay GSK’s multiple myeloma drug despite safety worriesGlaxoSmithKline’s potential first-in-class multiple myeloma drug belantamab mafodotin has taken a step closer to US approval after unanimous backing from a panel of expert advisers convened Share XFDA experts okay GSK’s multiple myeloma drug despite safety worrieshttps://pharmaphorum.com/news/fda-experts-okay-gsks-multiple-myeloma-drug-despite-safety-worries/
FDA reviewer warns of eye trouble with GSK’s myeloma ADCGlaxoSmithKline heads for an FDA advisory committee meeting this week for belantamab mafodotin – its much-touted treatment for Share XFDA reviewer warns of eye trouble with GSK’s myeloma ADChttps://pharmaphorum.com/news/fda-reviewer-warns-of-eye-trouble-with-gsks-myeloma-adc/
Kiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myelomaSanofi has struck an exclusive rights deal with Dutch biotech Kiadis focused on combining modified natural killer cells Share XKiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myelomahttps://pharmaphorum.com/news/sanofi-to-develop/
